Health Federation of Philadelphia is seeking to fill a C Change HCV Navigator position. This is a great opportunity provide on-site HCV services at Centers of Excellence across the city. See below for the job summary and specifications. View the full Read more…
Yesterday, a legal settlement was filed for federal court approval for the Eastern District of Pennsylvania that would expand Medicaid coverage for incarcerated Pennsylvanians who have Hepatitis C. This would provide approximately 5,000 incarcerated people known to have hepatitis C Read more…
A recent piece in MedPage Today highlights HCV screening guidelines and how they affect rates of testing. It provides an overview of the evolution of HCV screening guidelines as well as current issues, particularly the discussion of the merits of Read more…
A new study from the American Association for the Study of Liver Diseases reports that over 2 million people in the United States had current HCV infection during 2013‐2016. The findings of the study suggest that the previous 2013-2016 US HCV prevalence estimate Read more…
November 7 @ 3:00 pm – 5:00 pm EST Time: 3:00 – 5:00 PM EST Description: This 2 -hour webinar will review the basic information about hepatitis C that health and human service providers should discuss with program participants who identify as Lesbian, Read more…
October is Liver Cancer Awareness Month! We are highlighting resources and events that can help raise liver cancer awareness in populations affected by viral hepatitis. Resources – HepMag’s overview of liver cancer provides basic information on liver cancer, including prevention Read more…
On Tuesday 10/30, hear from providers and patients about the repercussions of a liver cancer diagnosis. Register here. The American Liver Foundation is pleased to present an upcoming webinar: On The Front Lines Of Liver Cancer Date: Tuesday, October 30th, 2018 Time: 12 Read more…
October is Liver Cancer Awareness Month! It’s always important to recognize the significant risks of chronic viral hepatitis on long-term health and survival. This month we are highlighting liver cancer, the fastest-growing cause of cancer death in the U.S. The Read more…
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa®(sofosbuvir 400mg/velpatasvir 100mg) and Harvoni®(ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly Read more…
“Taking Steps to Good Care & Long Term Health” is a free community forum on Thursday, November 8th, organized by the National AIDS Treatment Advocacy Project and co-sponsored by HepCAP. While HepCAP meetings are on hold, this morning forum is Read more…